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Abstract
Introduction: Plurihormonality of pituitary adenomas can be defined as the ability of an adenoma to express more than one pituitary
hormone. The application of immunohistochemistry to diagnose surgically removed pituitary tumours revealed that a great number of
pituitary adenomas are in fact plurihormonal. However, data on the incidence and the clinical relevance of the pituitary adenoma pluri-
hormonality are still scarce and controversial.
Material and methods: Hundred fifty-five pituitary adenomas, surgically removed, were studied immunohistochemically with the anti-
bodies against pituitary hormones or their subunits. Additionally, 40 adenomas were immunostained with Ki-67 antibody to evaluate the
proliferative potential.
Results: According to the World Health Organization (WHO) recommendations, we did not consider tumours expressing both FSH and
LH (gonadotropinomas) or somatoprolactinomas expressing both GH and prolactin as plurihormonal. Even with this limitation, plurihor-
monality was found to be a frequent finding in both hormonally active and clinically non-functioning pituitary adenomas. It was shown
that over one-third (36.1%) of the investigated adenomas expressed more than one hormone. Plurihormonality, especially that which is
connected with co-expression of ACTH, seems to be more frequent in the recurrent tumours. Plurihormonal adenomas also possess higher
Ki-67 indices, as compared to monohormonal tumours.
Conclusions: Plurihormonality is a frequent phenomenon in both hormonally active and clinically non-functioning pituitary adenomas.
It also seems to predict a higher risk of tumour recurrence. (Pol J Endocrinol 2010; 61 (1): 63–66)
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Streszczenie
Wstęp: Wielohormonalność gruczolaków przysadki jest definiowana jako ich zdolność do ekspresji więcej niż jednego hormonu przysad-
kowego. Zastosowanie immunohistochemii do diagnostyki usuniętych chirurgicznie guzów przysadki pozwoliło na stwierdzenie, że
w istocie znaczną część guczolaków przysadki jest wielohormonalna. Jednak dane o częstości występowania i znaczeniu klinicznym
wielohormonalności są skąpe i częściowo sprzeczne.
Materiał i metody: Sto pięćdziesiąt pięć chirurgicznie usuniętych gruczolaków przysadki zbadano immunohistochemicznie z użyciem
przeciwciał przeciw hormonom przysadkowym i/lub ich podjednostkom. Dodatkowo 40 gruczolaków zbadano za pomocą przeciwciała
Ki-67, w celu ustalenia ich potencjału proliferacyjnego.
Wyniki: Zgodnie z zaleceniami Światowej Organizacji Zdrowia (WHO, World Health Organization) nie zaliczono do gruczolaków wielo-
hormonalnych guzów z łączną ekspresją FSH i LH (gonadotropinoma) ani somatoprolactinoma wykazujących łączną ekspresję GH
i prolaktyny. Nawet przy tym ograniczeniu, wielohormonalność jest częstym zjawiskiem zarówno w przypadku hormonalnie czynnych,
jak i klinicznie nieczynnych gruczolaków przysadki. Wykazano, że w ponad jednej trzeciej (36.1%) badanych gruczolaków przysadki
wykrywa się obecność więcej niż jednego hormonu. Wielohormonalność, zwłaszcza związana z współwystępowaniem ACTH, jest częst-
sza w guzach nawrotowych. Guzy wielohormonalne wykazują także wyższy indeks Ki-67 w porównaniu z guzami monohormonalnymi.
Wnioski: Wielohormonalność jest częstym zjawiskiem zarówno w grupie guzów klinicznie czynnych, jak i grupie guzów klinicznie
nieczynnych hormonalnie. Ponadto wielohormonalność wydaje się wiązać z wyższym ryzykiem nawrotu guza.
(Endokrynol Pol 2010; 61 (1): 63–66)
Słowa kluczowe: gruczolaki przysadki, immunohistochemia, wielohormonalność, nawroty guzów
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Introduction
Plurihormonality of pituitary adenomas can be defined
as the ability of an adenoma to express more than one
pituitary hormone. According to the recommendations
of the WHO, the gonadotropinomas expressing both
gonadotropins, i.e. FSH and LH, are not considered plu-
rihormonal. The same concerns adenomas in patients
with acromegaly, secreting prolactin in addition to GH
[1]. Plurihormonal adenomas leading to the elevated
concentrations of more than one pituitary hormone in
blood are considered relatively rare. The application of
immunohistochemistry to diagnose surgically removed
pituitary tumours revealed that a great number of pitu-
itary adenomas, including the so-called “clinically non-
functioning” pituitary adenomas (CNFPA), are in fact
plurihormonal [2–8]. However, the data on the inciden-
ce and the clinical relevance of pituitary adenoma plu-
rihormonality remain scarce.
The aim of this study was to evaluate the incidence
of plurihormonality in a non-selected group of immu-
nohistochemically examined pituitary adenomas and
to answer the question whether the plurihormonality
of the tumours is relevant for their prognosis.
Material and methods
The archival material of 155 surgically removed pitu-
itary adenomas was studied. Paraffin sections of each
tumour were immunostained using the primary anti-
bodies against the following pituitary hormones or their
subunits: prolactin (PRL, polyclonal, Dako, Denmark),
growth hormone (GH, polyclonal, Dako or Immunon,
USA), LH (Dako, monoclonal), FSH (Dako, monoclo-
nal), TSH (monoclonal, Immunotech, France), ACTH
(polyclonal, Sigma), and alpha-subunit (alpha-SU, mo-
noclonal, Immunotech, France). Additionally, 40 ade-
nomas were immunostained with anti-Ki-67 antigen
(MIB-1) antibody (Dako-Cytomation, Denmark). Visu-
alization of the immune reactions was done by means
of streptavidin-biotin-peroxidase technique with use of
3,3’-diaminobenzidine as chromogen. The presence of
more than 1% of hormone immunopositive cells was
considered important. Statistical analysis of the numeric
data was done by means of McNemara’s and c2 tests (re-
currence rates) or ANOVA followed by LSD test (Ki-67
indices); statistical significance was at the level p < 0.05.
Results
The results are presented in Tables I–III. As can be seen,
over one third of pituitary adenomas examined by im-
munohistochemistry are plurihormonal (Table I). If, fol-
lowing the WHO recommendations, we do not consi-
der GH/PRL adenomas in acromegaly or FSH/LH ade-
nomas as plurihormonal, then plurihormonality is most
frequent in clinically non-functioning adenomas
(CNFPA) (see Table I). Approximately 1/5 of the inve-
stigated adenomas were recurrent. The recurrence rate
is highest in case of gonadotropinomas (45.7%). Howe-
ver, if we exclude this type of adenoma from the group
of monohormonal tumours, the recurrence rate of plu-
Table III. Clinically non-functioning pituitary adenomas
(CNFPA)
Tabela III. Klinicznie nieczynne gruczolaki przysadki
(CNFPA)
Total 85/155 (55.2%) Recurrent
29/85 (34.1%)
“Pure” 35/85 (41.1%) Recurrent
gonadotropinomas 16/35 (45.7%)
Monohormonal 7/85 (8.2%) Recurrent
(excluding 4/7 (57.1%)
gonadotropinomas)
Plurihormonal 38/85 (44.1%) Recurrent
 9/38 (23.7%)
Inactive =5/85 (5.9%) Recurrent
 0/5 (0%)
Table I. Incidence of plurihormonal pituitary adenomas
Tabela I. Zachorowalność na gruczolaki wielohormonalne
przysadki
Total 56/155 (36.1%)
Acromegaly
including GH/PRL 18/29 (62.1%)
excluding GH/PRL 7/29 (24.1%)
Cushing’s disease 4/14 (28.6%)
CNFPA 38/85 (44.7%)
Table II. Recurrence rate of pituitary adenomas
Tabela II. Wskaźniki występowania nawrotów gruczolaków
przysadki
Total 32/155 (20.6%)
Plurihormonal monohormonal 10/56 (17.8%)
Including gonadotropinomas 22/99 (22.2%)
Excluding gonadotropinomas 6/64 (9.4%)
Acromegaly 2/29 (6.9%)
GH/PRL 1/18 (5.5%)
Plurihormonal (GH/alfaSU) 1/7 (14.3%)
Cushing’s disease 3/14 (21.4%)
Plurihormonal 3/4 (75%)
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rihormonal adenomas is twice as high (17.8% v. 9.4%),
although the difference is not significant statistically.
A statistically significant difference in the recurrence rate
is found in corticotropinomas manifesting themselves
as Cushing’s disease. All the recurrent tumours obse-
rved in patients with Cushing’s disease were pluri-
hormonal (Table II). In the case of CNFPA, the highest
recurrence rate is observed in monohormonal adeno-
mas. However, the number of such tumours is relative-
ly low, and, interestingly, almost all recurrent adeno-
mas in this group (3/4) were “silent” (i.e. not manifested
as Cushing’s disease) corticotropinomas. The next po-
sition among the recurrent CNFPAs belongs to “pure”
gonadotropinomas. In contrast, no recurrent tumours
were found in the group of hormonally immunonega-
tive tumours (Table III). We also analyzed the relation-
ship between tumour recurrence and expression of
ACTH in plurihormonal CNFPA. Some tendency to-
wards a higher recurrence rate was observed in the gro-
up of plurihormonal CNFPS co-expressing ACTH, as
compared to ACTH-negative tumours (6/17, 35.3%
v. 2/14, 14.2%, respectively). Moreover, the mean Ki-67
index (% of Ki-67-immunopositive cell nuclei), calcula-
ted for plurihormonal tumours, was significantly higher
than the monohormonal adenoma group (6.0 ± 1.9%
vs. 1.7 ± 0.5%, mean ± SEM, p < 0.05).
Discussion
Our data show that plurihormonality is a frequent phe-
nomenon in both hormonally active and clinically non-
functioning pituitary adenomas. Their frequency in our
material (36.1%) is very similar to that (31%) reported
earlier by Ho et al. [5]. This finding supports the opi-
nion of quoted authors that the immunostaining of all
pituitary hormones is mandatory for correct classifica-
tion of pituitary adenomas. Earlier studies with the ap-
plication of double immunostaining at the light micro-
scopy and the electron microscopy levels showed that
the multiple hormones are expressed within the same
tumoural cell, and even within the same secretory gra-
nule [9]. Although double immunostaining was not
applied in the present study, the sum of the percenta-
ges of cells immunopositive for different hormones
often exceeded 100. This means that the cells must pre-
sent double or even triple hormone immunopositivity.
These findings indicate that plurihormonal adenomas
are constituted from plurihormonal cells rather than
from multiple cellular lines expressing different pitu-
itary hormones. The question arises whether the expres-
sion of multiple hormones in tumoural cells is relevant
for their natural history, and specifically whether it po-
ssesses a prognostic value. The recurrence of pituitary
adenoma after surgery may depend on early or late dia-
gnosis and the skilfulness of the neurosurgeon, but also
depends on tumour aggressiveness. The latter is linked
with tumour invasiveness, i.e. the ability of the tumour
cells to invade the adjacent structures consequently
enabling total excision of the tumour, and with its high
proliferation potency. The latter is usually measured by
calculation of the percentage of cell nuclei positively
immunostained with antibody to Ki-67 antigen (Ki-67
index). Generally, Ki-67 index is positively correlated
with tumour invasiveness and recurrence, although
some exceptions have been observed, and the low Ki-
67 index can be noticed in aggressive tumours, and, in
contrast, the high proliferation index may occur in in-
dolent adenomas [10]. It was important to see whether
plurihormonality increases the risk of the tumour re-
currence. Although the high recurrence rate in our
material concerns gonadotropinomas, which according
to WHO recommendations are considered “monohor-
monal” adenomas, and monohormonal ACTH-immu-
nopositive adenomas without Cushing’s disease mani-
festation (“silent” corticotropinomas), in the remaining
types of adenomas the plurihormonality seems to be
linked with the increased risk of tumour recurrence.
This suggestion is supported by our finding that the
mean value of Ki-67 index in plurihormonal pituitary
adenomas is significantly higher than in monohormo-
nal tumours. In our earlier paper we showed that pluri-
hormonal adenomas present higher values of another
proliferation index, namely proliferating cells nuclear
antigen, PCNA [11]. Our observation of the higher re-
currence rate in cases of plurihormonal versus mono-
hormonal corticotropinomas with Cushing’s disease is
compatible with the findings of Desai et al. [12]. The
quoted authors have found that corticotropinomas co-
secreting the alpha-subunit are more aggressive and
have a higher recurrence rate than corticotropinomas
without the expression of this peptide. The increased
risk of tumour recurrence seems also to be linked with
ACTH co-expression in plurihormonal CNFPA, which
corroborates with the data of Bradley et al. [13]. We sug-
gest that plurihormonality of pituitary adenomas, espe-
cially that linked with ACTH co-expression, seems to
predict a higher risk of tumour recurrence. However,
this presumption needs further studies based on higher
number of examined tumours.
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